Vincristine Sulfate for Injection

Vincristine is an active ingredient extracted from the Apocynaceae plant Catharanthus roseus. The anti-tumor target is microtubules, mainly inhibiting the polymerization of tubulin and affecting the formation of spindle microtubules. It stops mitosis at metaphase. It can also interfere with protein metabolism and inhibit the activity of RNA polymerase, and inhibit the synthesis of cell membrane lipids and the transport of amino acids on the cell membrane. Vincristine has a greater inhibitory effect on transplanted tumors than vinblastine and has a wider anti-tumor spectrum. In addition to being effective against tumor strains sensitive to vinblastine, it also has effects on mouse Ridgeway osteosarcoma, Mecca lymphosarcoma, X-5563 myeloma, etc. There is no cross-resistance between vincristine, vinblastine and vindesine, and vincristine has the strongest neurotoxicity among the three.

The chemical name of this product is vincristine sulfate. Its structural formula is: Molecular formula: C46H56NO10H2SO4 Molecular weight: 923.04

This product is a white or off-white loose or amorphous solid, hygroscopic, and easily turns yellow when exposed to light or heat.

①. Acute leukemia, especially childhood acute leukemia, and has significant efficacy on acute lymphocytic leukemia. ②. Malignant lymphoma. ③. Germ cell tumors. ④. Small cell lung cancer, Ewing sarcoma, Wilms tumor, neuroblastoma. ⑤. Breast cancer, chronic lymphocytic leukemia, digestive tract cancer, melanoma, multiple myeloma, etc.

The adult dose is 1-2 mg (or 1.4 mg/m2) with a maximum dose of no more than 2 mg. For patients over 65 years old, the maximum dose is 1 mg each time. For children, the dose is 75 μg/kg or 2.0 mg/m2, once a week by intravenous injection or flushing. Combination chemotherapy is used for 2 consecutive weeks as a cycle.

1. Dose-limiting toxicity is nervous system toxicity, which mainly causes peripheral nerve symptoms, such as finger and neurotoxicity, which is related to the cumulative dose. Toe numbness, sluggish or absent tendon reflexes, and peripheral neuritis. Abdominal pain, constipation, and paralytic ileus are occasionally seen. Motor nerves, sensory nerves, and cranial nerves may also be damaged and produce corresponding symptoms. Neurotoxicity often occurs in people over 40 years old. Children have better tolerance than adults. Patients with malignant lymphoma are more prone to neurotoxicity than other tumor patients. 2. Bone marrow suppression and gastrointestinal reactions are relatively mild. 3. There is a local tissue irritation effect, and the drug solution cannot leak out, otherwise it may cause local necrosis. 4. Hair loss and occasional changes in blood pressure may be seen.

1. Azole series antifungal agents (itraconazole) increase the side effects of the muscle and nervous system. If side effects are found, appropriate treatments such as dose reduction, suspension or discontinuation should be carried out. Itraconazole has the effect of inhibiting hepatocyte cytochrome P-4503A. Vincristine is metabolized by hepatocyte cytochrome P-4503A. Co-administration can inhibit the metabolism of vincristine. 2. Combined use with phenytoin sodium reduces the absorption of phenytoin sodium or causes hypermetabolism. 3. Combined use with platinum-containing anti-sub- and anti-malignant tumor agents may enhance the eighth cranial nerve disorder. 4. Combined use with L-asparaginase may enhance the disorders of the nervous system and blood system. In order to minimize toxicity, vincristine sulfate can be used 12-24 hours before the administration of L-asparaginase.

Shade, sealed and stored

1mg

Fresenius Kabi (Wuhan) Pharmaceutical Co., Ltd.

• Founded in:

  2012-07-20

• Address:

  Biomedical Park, No. 858 Gaoxin Avenue, Wuhan East Lake New Technology Development Zone (Wuhan Area of Free Trade Zone)

• Tax NO.:

  914201005979383918

• Registered Funds:

  230 million yuan

• Website:

  Log in to view

• Email:

  Log in to view